{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "company-controlled", "type": "clause", "offset": [33, 51]}, {"key": "directly-or-indirectly", "type": "clause", "offset": [142, 164]}, {"key": "a-portion", "type": "definition", "offset": [165, 174]}, {"key": "the-capital", "type": "clause", "offset": [178, 189]}, {"key": "the-majority", "type": "clause", "offset": [205, 217]}, {"key": "general-meetings-of-shareholders", "type": "clause", "offset": [242, 274]}, {"key": "this-company", "type": "definition", "offset": [278, 290]}, {"key": "an-agreement", "type": "clause", "offset": [380, 392]}, {"key": "other-partners", "type": "definition", "offset": [408, 422]}, {"key": "contrary-to", "type": "definition", "offset": [456, 467]}, {"key": "the-interest", "type": "clause", "offset": [468, 480]}, {"key": "of-the-company", "type": "clause", "offset": [481, 495]}, {"key": "de-facto", "type": "definition", "offset": [520, 528]}, {"key": "in-the-general", "type": "clause", "offset": [577, 591]}, {"key": "members-of-the", "type": "clause", "offset": [751, 765]}, {"key": "supervisory-bodies", "type": "definition", "offset": [796, 814]}], "snippet": "means SERVIER SAS, and any other company controlled by SERVIER SAS, with a company being considered as controlling another: (a) when it holds directly or indirectly a portion of the capital which provides the majority of the voting rights in general meetings of shareholders of this company; (b) when it holds solely the majority of the voting rights in this company by virtue of an agreement concluded with other partners or shareholders and which is not contrary to the interest of the company; (c) when it determines de facto, by voting rights which it holds, the decisions in the general meetings of shareholders of this company; (d) when it is a partner or shareholder of this company and holds the power to nominate or to revoke the majority of members of the administrative, management or supervisory bodies or (e) in any event, when it holds, directly or indirectly, a portion of voting rights greater than 40% and when no other partner or shareholder holds directly or indirectly a portion which is greater than its own.", "size": 7, "samples": [{"hash": "fpau0DCF9Vv", "uri": "https://servier.gr/wp-content/uploads/sites/2/2025/01/SERVIER-Data-Privacy-Policy_eng-27.7.2018.pdf", "label": "servier.gr", "score": 17.9378199941, "published": false}, {"hash": "wio7vm4koW", "uri": "https://servier.gr/wp-content/uploads/sites/4/2021/06/Data-Privacy-Policy.pdf", "label": "servier.gr", "score": 8.3826150894, "published": false}, {"hash": "7jMKEb2ID02", "uri": "https://servier.ie/wp-content/uploads/sites/20/2021/12/Data-Privacy-Policy-Ireland-July-2021.pdf", "label": "servier.ie", "score": 6.7549624443, "published": false}], "hash": "342f6acfcd777763209ce590c2635f47", "id": 1}, {"snippet_links": [{"key": "a-corporation", "type": "clause", "offset": [32, 45]}, {"key": "organized-and-existing", "type": "clause", "offset": [46, 68]}, {"key": "the-laws", "type": "definition", "offset": [75, 83]}, {"key": "having-a", "type": "definition", "offset": [98, 106]}, {"key": "place-of-business", "type": "definition", "offset": [107, 124]}], "snippet": "means Les Laboratoires Servier, a corporation organized and existing under the laws of France and having a place of business located at \u2587\u2587 \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587.", "size": 6, "samples": [{"hash": "ib3o6qlxVJZ", "uri": "/contracts/ib3o6qlxVJZ#servier", "label": "License Agreement (Allogene Therapeutics, Inc.)", "score": 30.3442840576, "published": true}, {"hash": "hWAQrrYmJk", "uri": "/contracts/hWAQrrYmJk#servier", "label": "License Agreement (Cellectis S.A.)", "score": 30.3114299774, "published": true}, {"hash": "gjqpYGfA6Qf", "uri": "/contracts/gjqpYGfA6Qf#servier", "label": "License Agreement (Cellectis S.A.)", "score": 30.1909656525, "published": true}], "hash": "00263a15ffd87c91a7d89de8bb3c05f9", "id": 2}, {"snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [29, 41]}], "snippet": "has the meaning set forth in the preamble.", "size": 5, "samples": [{"hash": "dZZYKXYAuOi", "uri": "/contracts/dZZYKXYAuOi#servier", "label": "License Agreement (Black Diamond Therapeutics, Inc.)", "score": 34.3593444824, "published": true}, {"hash": "5Y3X6znvggn", "uri": "/contracts/5Y3X6znvggn#servier", "label": "License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.3148536682, "published": true}, {"hash": "eq5ER0Oz68j", "uri": "/contracts/eq5ER0Oz68j#servier", "label": "License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 28.2416152954, "published": true}], "hash": "550c6397310458225d7327158d62c082", "id": 3}, {"snippet_links": [], "snippet": "means, collectively, Les Laboratoires Servier and Institut de Recherches Internationales Servier.", "size": 4, "samples": [{"hash": "ingeYLFFbsO", "uri": "/contracts/ingeYLFFbsO#servier", "label": "Asset Contribution Agreement (Allogene Therapeutics, Inc.)", "score": 34.8343582153, "published": true}, {"hash": "br1i3ZqYl4z", "uri": "/contracts/br1i3ZqYl4z#servier", "label": "Asset Contribution Agreement (Allogene Therapeutics, Inc.)", "score": 29.7501716614, "published": true}, {"hash": "66QgFuChaIQ", "uri": "/contracts/66QgFuChaIQ#servier", "label": "Asset Contribution Agreement (Allogene Therapeutics, Inc.)", "score": 29.7008895874, "published": true}], "hash": "964ad03857157578eebcefb1699f0605", "id": 4}, {"snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [45, 57]}, {"key": "to-this-agreement", "type": "clause", "offset": [58, 75]}], "snippet": "shall have the meaning given to such term in the preamble to this Agreement.", "size": 2, "samples": [{"hash": "b37V8TSNHvg", "uri": "/contracts/b37V8TSNHvg#servier", "label": "Product Research, Development, License and Commercialization Agreement (Intercept Pharmaceuticals Inc)", "score": 23.7378501892, "published": true}, {"hash": "kJbZuwKctG8", "uri": "/contracts/kJbZuwKctG8#servier", "label": "Product Research, Development, License and Commercialization Agreement (Intercept Pharmaceuticals Inc)", "score": 23.6748809814, "published": true}], "hash": "d111ef8603f610c3c204abaf4cc3b6b3", "id": 5}, {"snippet_links": [{"key": "a-delaware-limited-liability-company", "type": "clause", "offset": [36, 72]}, {"key": "person-defined", "type": "clause", "offset": [81, 95]}, {"key": "counterparty-agreement", "type": "clause", "offset": [118, 140]}], "snippet": "means Servier Pharmaceuticals, LLC, a Delaware limited liability company and the Person defined as \u201cPurchaser\u201d in the Counterparty Agreement.", "size": 2, "samples": [{"hash": "4Pi0J4KdOD0", "uri": "/contracts/4Pi0J4KdOD0#servier", "label": "Purchase and Sale Agreement (Agios Pharmaceuticals, Inc.)", "score": 35.5817947388, "published": true}, {"hash": "kcBX3s2CLRY", "uri": "https://investor.agios.com/static-files/3f32368f-4f96-4df2-85f6-22d5d16e4bab", "label": "investor.agios.com", "score": 19.2390460968, "published": false}], "hash": "ef41df2a28ef09a02fe5ddedaf036eac", "id": 6}, {"snippet_links": [{"key": "first-paragraph", "type": "definition", "offset": [40, 55]}, {"key": "this-agreement", "type": "clause", "offset": [59, 73]}], "snippet": "shall have the meaning set forth in the first paragraph of this Agreement.", "size": 2, "samples": [{"hash": "27KoRNmrSri", "uri": "/contracts/27KoRNmrSri#servier", "label": "License Agreement (Osteologix, Inc.)", "score": 21.8706359863, "published": true}, {"hash": "a7VR7a4TvHb", "uri": "/contracts/a7VR7a4TvHb#servier", "label": "Collaboration Agreement (Pharmacyclics Inc)", "score": 21.0, "published": true}], "hash": "a941281cdb6eb43cf65061ab519efcd2", "id": 7}, {"snippet_links": [{"key": "the-definition-of", "type": "definition", "offset": [29, 46]}, {"key": "servier-agreement", "type": "definition", "offset": [47, 64]}], "snippet": "has the meaning set forth in the definition of Servier Agreement.", "size": 2, "samples": [{"hash": "62bJpWkQVkQ", "uri": "/contracts/62bJpWkQVkQ#servier", "label": "License Agreement (Precision Biosciences Inc)", "score": 35.234085083, "published": true}, {"hash": "eNKlXbF8gSn", "uri": "/contracts/eNKlXbF8gSn#servier", "label": "License Agreement (Tg Therapeutics, Inc.)", "score": 35.1601638794, "published": true}], "hash": "029b820cb21c87a66d8e35b8ec2e1d85", "id": 8}, {"snippet_links": [{"key": "other-term", "type": "clause", "offset": [115, 125]}, {"key": "this-exhibit", "type": "definition", "offset": [134, 146]}, {"key": "capital-letter", "type": "definition", "offset": [154, 168]}, {"key": "the-gdpr", "type": "definition", "offset": [203, 211]}, {"key": "in-the-agreement", "type": "clause", "offset": [215, 231]}], "snippet": "refers to the SERVIER entity(ies) as party(ies) to the Agreement and/or all or part of its (their) Affiliates. Any other term used in this Exhibit with a capital letter has the meaning ascribed to it in the GDPR or in the Agreement.", "size": 2, "samples": [{"hash": "55vgS2WJjmV", "uri": "/contracts/55vgS2WJjmV#servier", "label": "Sponsorship Agreement", "score": 36.1028327942, "published": true}], "hash": "52bd9bcaba7430a5221ca64fc48a4d2a", "id": 9}, {"snippet_links": [], "snippet": "Preamble \u201cServier Indemnitee\u201d 16.1", "size": 1, "samples": [{"hash": "hVFkXgrCyWk", "uri": "/contracts/hVFkXgrCyWk#servier", "label": "Exclusive License and Collaboration Agreement (Cti Biopharma Corp)", "score": 28.3347015381, "published": true}], "hash": "bd6cf7980f72499f65ac3d1e7570a6c5", "id": 10}], "next_curs": "ClQSTmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjALEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIQc2VydmllciMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Servier", "snippet": "means SERVIER SAS, and any other company controlled by SERVIER SAS, with a company being considered as controlling another: (a) when it holds directly or indirectly a portion of the capital which provides the majority of the voting rights in general meetings of shareholders of this company; (b) when it holds solely the majority of the voting rights in this company by virtue of an agreement concluded with other partners or shareholders and which is not contrary to the interest of the company; (c) when it determines de facto, by voting rights which it holds, the decisions in the general meetings of shareholders of this company; (d) when it is a partner or shareholder of this company and holds the power to nominate or to revoke the majority of members of the administrative, management or supervisory bodies or (e) in any event, when it holds, directly or indirectly, a portion of voting rights greater than 40% and when no other partner or shareholder holds directly or indirectly a portion which is greater than its own.", "size": 39, "id": "servier", "examples": ["<strong>Servier</strong> shall pay to Miragen the amount invoiced within [*] days after the receipt of the invoice.", "For clarity, nothing in this Section 7.1 with respect to MacroGenics\u2019 obligation to transfer MacroGenics Know-How to <strong>Servier</strong> shall limit MacroGenics\u2019 right to use any such MacroGenics Know-How to fulfill MacroGenics\u2019 obligations to Manufacture and supply Licensed Product to <strong>Servier</strong> under this Agreement or the Supply Agreement.", "<strong>Servier</strong> may not use any MacroGenics Know-How (or permit any Third Party to use any MacroGenics Know-How) outside the <strong>Servier</strong> Territory, nor for any products other than the Licensed Products, except as may otherwise be agreed by MacroGenics and <strong>Servier</strong> (including as provided in Sections 4.1 and 4.2).", "For the avoidance of doubt, any information disclosed by MacroGenics to <strong>Servier</strong> prior to the Effective Date pursuant to the Non-Disclosure Disclosure Agreement between MacroGenics and <strong>Servier</strong> dated *** (the \u201cExisting Confidentiality Agreement\u201d) shall be treated as Confidential Information for all purposes under this Agreement.", "<strong>Servier</strong> shall comply with all applicable Laws in the <strong>Servier</strong> Territory, including local regulations and ICH guidelines.", "MacroGenics shall provide <strong>Servier</strong> regularly prepared minutes of material meetings with the *** regarding Licensed Products in the Field in the MacroGenics Territory and available material teleconference reports with the *** pertaining to Licensed Products in the Field in the MacroGenics Territory.", "Within *** after the end of each Calendar Quarter during which there are Net Sales giving rise to a payment obligation under Section 9.4 or 9.5, <strong>Servier</strong> shall submit to MacroGenics a report identifying for each Licensed Product, the Net Sales for such Licensed Product for each country in the <strong>Servier</strong> Territory for such Calendar Quarter, the calculation of royalties (including gross sales and all deductions taken from gross sales), and the royalties and the sales milestones payable to MacroGenics.", "To the extent permitted by Regulatory Authorities, MacroGenics shall have the right to have a senior, experienced employee participate as an observer in meetings with the *** or their agents, as well as participate in internal meetings or discussions of <strong>Servier</strong> occurring immediately before or after, and related to, such meetings, and shall be provided with advance access to <strong>Servier</strong>\u2019s materials prepared for such meetings.", "As between the Parties, <strong>Servier</strong> shall be responsible for reporting all adverse drug reactions/experiences to the appropriate regulatory authorities in countries in the <strong>Servier</strong> Territory, and MacroGenics shall be responsible for reporting all adverse drug reactions/experiences to the appropriate regulatory authorities in the MacroGenics Territory, in accordance with the appropriate laws and regulations of the relevant countries and authorities.", "Notwithstanding the foregoing sentence, MacroGenics shall not initiate any such lawsuit or other enforcement action asserting any such Joint Patents without first consulting with <strong>Servier</strong> and giving good faith consideration to any reasonable objection from <strong>Servier</strong> regarding MacroGenics\u2019 proposed course of action."], "related": [["gsk", "GSK", "GSK"], ["merck", "Merck", "Merck"], ["isis", "ISIS", "ISIS"], ["bms", "BMS", "BMS"], ["novartis", "Novartis", "Novartis"]], "related_snippets": [], "updated": "2025-07-18T05:45:24+00:00"}, "json": true, "cursor": ""}}